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Abstract
Immunocompromised individuals tend to suffer from influenza longer with more serious complications than otherwise
healthy patients. Little is known about the impact of prolonged infection and the efficacy of antiviral therapy in these
patients. Among all 189 influenza A virus infected immunocompromised patients admitted to ErasmusMC, 71 were
hospitalized, since the start of the 2009 H1N1 pandemic. We identified 11 (15%) cases with prolonged 2009 pandemic virus
replication (longer than 14 days), despite antiviral therapy. In 5 out of these 11 (45%) cases oseltamivir resistant H275Y
viruses emerged. Given the inherent difficulties in studying antiviral efficacy in immunocompromised patients, we have
infected immunocompromised ferrets with either wild-type, or oseltamivir-resistant (H275Y) 2009 pandemic virus. All ferrets
showed prolonged virus shedding. In wild-type virus infected animals treated with oseltamivir, H275Y resistant variants
emerged within a week after infection. Unexpectedly, oseltamivir therapy still proved to be partially protective in animals
infected with resistant virus. Immunocompromised ferrets offer an attractive alternative to study efficacy of novel antiviral
therapies.
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Introduction
During the first 12 months of the 2009 influenza A/H1N1 virus
(pH1N1) pandemic an estimated 284,000 patients died and
hospitalization rates were considerably higher than for seasonal
influenza [1]. Althoughmany severe cases were observed in otherwise
healthy patients under 50 years of age, most fatal cases during this
pandemic were patients belonging to the traditional high risk groups
for developing severe disease, like very young children, the elderly
and chronically ill patients [2]. In these patients, which in most cases
have sub-optimal immune responses, influenza viruses often persists
longer and tend to spread more readily into the lower respiratory
tract [3,4,5,6]. These observations are in contrast to those in
otherwise healthy patients younger than 65 years, for which influenza
usually remains a self-limiting upper respiratory tract infection [7,8].
It has been recognized that every winter season a significant
number of immunocompromised patients are admitted to a
hospital with influenza [9,10]. For example, of the total 335
influenza A virus infected patients being diagnosed upon
admission to ErasmusMC - a tertiary university hospital - between
August 2009 and July 2012, 113 (34%) had an underlying
condition that classified them as being immunocompromised [11].
Since immunocompromised patients are more likely to acquire
influenza [12,13], showing relatively high influenza-associated
mortality [4,14,15,16,17,18,19,20,21,22,23,24], effective antiviral
prophylaxis and treatment protocols are of crucial importance for
these patients.
Unfortunately, present antiviral strategies are merely based on
clinical trials conducted in otherwise healthy patients [25], since
randomized clinical trials in immunocompromised patients are, for
both ethical and practical reasons, difficult to perform. Further-
more, the degree and cause of a patient’s immunocompromised
state is variable and consequently, clinical outcome of infection
may vary accordingly.
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Although antiviral therapy has a documented positive effect on
clinical outcome in immunocompromised patients [3,26,27,28],
current antiviral strategies are far from satisfying. This may be
explained not only by the lack of evidence based strategies
adjusted for immunocompromised patients [4,28], but also by the
oral and inhaled administration routes which complicate admin-
istration in very young and critically ill patients [29,30,31,32,33].
Furthermore, since physicians may not consider the diagnosis
influenza initially, antiviral therapy is often initiated beyond
48 hours [34], and accompanied by the emergence of an
oseltamivir resistant virus [35].
We investigated the incidence of prolonged virus shedding and
emergence of antiviral resistance by studying the course of
infection of the immunocompromised patients infected with
pH1N1 virus treated in our university hospital. These phenomena
were studied in more detail in immunocompromised ferrets
experimentally infected with pH1N1 virus, that closely mimic
immunocompromised patients with influenza. These ferrets all
showed prolonged virus shedding and emergence of antiviral
resistance. Unexpectedly, the group of immunocompromised
ferrets treated with an oseltamivir dose equivalent to a 450 mg
dose (twice daily) in humans, had a higher survival rate than
similarly untreated animals when infected with an oseltamivir
resistant virus.
Results
Prolonged shedding and resistance development in
immunocompromised patients
We quantified prolonged virus replication and resistance
development in immunocompromised patients retrospectively,
who were infected between August 2009 and July 2012, and
hospitalized in our tertiary hospital with influenza A virus. Among
the 189 RT-qPCR confirmed influenza A virus infected patients
(median age = 22.3, range= 0–81), 71 (38%) patients were
classified as being immunocompromised (Table 1). These patients
were either cancer patients on chemotherapy (CC), solid organ
transplant (SOT) or patients with an auto-immune disease on
immune suppression, HIV-infected patients or patients with
another cause of compromised immune status. From 37 (52%)
patients, no follow up samples were taken (physician’s choice) and
18 (25%) patients had cleared the virus within 14 days. Of the
immunocompromised patients from whom follow up was avail-
able, 11 (15%) had a pH1N1 virus infection and were shedding
virus for more than 14 days, despite receiving oseltamivir or
oseltamivir/zanamivir therapy (Figure 1). Prolonged replication of
influenza A/H3N2 virus was found in 5 (7%) cases (data not
shown). In 5 (7%) of the immunocompromised patients with an
influenza pH1N1 virus infection the oseltamivir resistance
mutation H275Y in the neuraminidase was detected by RT-
PCR during oseltamivir mono or oseltamivir/zanamivir combi-
nation therapy.
Immunosuppressive treatment of ferrets
We investigated whether the observations on prolonged
virus replication and emergence of antiviral resistance in
immunocompromised patients could be mimicked in ferrets
receiving a cocktail of immunosuppressive drugs similar to that
administered to SOT patients (combination of mycophenolate
mofetil (MMF), tacrolimus and predisolone). First, pharmaco-
kinetics were studied following oral administration of ferrets
(n = 4) given 20 mg/kg MMF, 1 mg/kg tacrolimus and 8 mg/
kg prednisolone (Table 2 and Supporting information Figure
S1). From the concentration over time profiles, peak (Cmax)
levels for MPA, the active form of MMF, were 65630 mg/mL
with trough (C12) levels becoming undetectable after 8 hours.
Peak and trough tacrolimus levels were 86630 ng/mL and
14630 ng/mL respectively. We determined area under the
curve (AUC0–12) values of 54614 mg?h/mL for MPA and
4386265 ng?h/mL for tacrolimus. In humans, MPA AUC0–12
values between 30–60 mg?h/mL and tacrolimus trough levels
between 5–15 ng?h/mL are proposed [36,37]. Because of a
shorter MPA half life (t1/2) and high tacrolimus peak levels, we
further optimized the ferret regime by administration of the
cocktail every 12 hours containing half of the initial tacrolimus
dose (0.5 mg/kg).
Next, the effects of this cocktail on the ferret immune
competence were studied. To this end, 6 groups of ferrets were
inoculated intratracheally on day 0 with a wild type or H275Y
mutant pH1N1 virus (Figure 2A). Of note, both viruses had been
isolated by clonal culturing from the same respiratory sample
taken from an immunocompromised patient on oseltamivir
therapy [38]. Three days earlier, immunosuppressive therapy
was started for all animals, except for the animals in control groups
1 and 4. On day 13, blood was collected and influenza antibody
titers were determined in the ferret sera (Figure 2B). As compared
to day 0, both the animals in the control groups (groups 1 and 4)
and those on immunosuppressive therapy (groups 2, 3, 5 and 6),
developed serum hemagglutination inhibiting (HI) antibody titers
against the inoculated virus. However, antibody titers in the
animals on immunosuppressive therapy were significantly lower
(P,0.0001) (Figure 2B and S2A–D). As an indication of an
activated immune response, body temperatures of all animals in
the control groups raised from day 2, as compared to baseline, and
remained higher until day 6 (Figure 2C and S2E–F). No significant
change in body temperature was detected in the infected animals
on immunosuppressive therapy, as is often seen in immunocom-
promised patients [39]. Finally, pathological examination of
lymphoid tissues of animals sacrificed on day 21 revealed deficient
lymphoid follicle formation in tracheobronchial lymph nodes and
lymphocyte depletion in the tonsils of animals on immunosup-
pressive therapy (Figure 2D).
Author Summary
Immunocompromised patients, such as transplant recipi-
ents on immune suppressive therapy, are a substantial and
gradually expanding patient group. Upon influenza virus
infection, these patients clear the virus less efficiently and
are more likely to develop severe pneumonia than
immunocompetent individuals. Existing antiviral strategies
are far from satisfactory for this patient group, as they
show limited effectiveness with frequent emergence of
antiviral resistance. For ethical and practical reasons
antiviral efficacy studies are hard to conduct in these
patients. Therefore, we developed an immunocompro-
mised ferret, mimicking an immune suppressive regimen
used for solid organ transplant recipients. Upon infection
with 2009 pandemic influenza A/H1N1 virus these animals,
like immunocompromised patients, develop severe respi-
ratory disease with prolonged virus excretion. Interesting-
ly, all immunocompromised ferrets on oseltamivir therapy
excreted oseltamivir resistant viruses (H275Y) within one
week after start of treatment. Furthermore, high dose
oseltamivir therapy still proved to be partially effective
against these oseltamivir resistant viruses. These immuno-
compromised ferrets provide a useful tool in the develop-
ment of novel antiviral approaches for immunocompro-
mised patients suffering from influenza.
Persisting Influenza in Immunocompromised Host
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Prolonged virus shedding in immunocompromised
ferrets
The animals of groups 1, 2 and 3 had been inoculated with
oseltamivir sensitive (wild type; H275) and the animals in
groups 4, 5 and 6 with oseltamivir resistant virus (mutant;
H275Y) (Figure 2A and 3). On day 2 post infection (p.i.), all 6
animals were found positive by virus culture from their throat
(Figure 3 and S3). On day 3 p.i., virus was detected in the nose
of five (group 1) wild type inoculated animals and one (group 4)
animal inoculated with oseltamivir resistant virus (Figure S3A
and C). In the animals infected with wild type virus, which
were treated with oseltamivir (group 3), replication of virus in
the nose was delayed as compared to the oseltamivir treated
animals inoculated with mutant virus (group 6). By day 9, all
animals in the control groups had cleared the virus. The
surviving immunocompromised ferrets in the other groups
were shedding virus for at least another 7 days, except for those
in group 5. These animals had cleared the virus from the nose
and throat by day 13 (Figure 3C and D).
Oseltamivir therapy and emergence of oseltamivir
resistance
In the animals of groups 3 and 6, oseltamivir therapy (10 mg/kg
twice daily) was started 24 hours after infection and continued for
21 days (Table 2 and S2C). Until day 7, when still 6 animals were
alive in each group, the viral loads in the oseltamivir treated
animals infected with wild type virus was significantly lower on
days 3, 4 and 5 in the nose and on days 3 to 7 in the throat
(P,0.001). Such difference was not observed in the animals
infected with oseltamivir resistant virus (Figure 3C and D).
Emergence of oseltamivir resistance was studied in the animals
infected with wild type virus (groups 1, 2 and 3) using an RT-PCR
assay specifically detecting the H275Y oseltamivir resistance mutation
(Figure 4) [40]. From day 8 onward, the H275Y mutation emerged in
the virus population of all oseltamivir treated animals in both the nose
and throat. The H275Y mutant became the major genotype 2 or 3
days later. No oseltamivir resistant viruses were detected in the
immunocompromised wild-type virus infected animals that did not
receive oseltamivir.
Figure 1. Viral load, antiviral therapy and resistance detection in immunocompromised patients hospitalized with a prolonged
pH1N1 virus infection. From 11 immunocompromised patients the viral load in respiratory specimens obtained during the courses of illness are
shown in bars. Patients 1, 2 and 10 were solid organ transplant patients. Patients 3, 4, 5, 7, 8, 9 and 11 were cancer patients on chemotherapy. Patient
6 was treated for cerebral vasculitis. The dotted line in each figure indicates the lower limit of detection of the influenza A virus RT-qPCR detection
assay. Data are presented as the number of virus particles per ml. Bar colours indicate the absence (green) or presence (magenta) of the H275Y
oseltamivir resistance mutation as detected by RT-PCR. If both genotypes were detected in a sample, the proportion is stacked. Bars are coloured
white for those respiratory samples in which the H275Y genotype could not be determined or in cases when genotyping was not performed. The
duration of oseltamivir monotherapy and oseltamivir/zanamivir combination therapy is indicated, respectively, by blue and dotted blue shading.
doi:10.1371/journal.ppat.1003343.g001
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Increased survival of immunocompromised animals
treated with oseltamivir
Unexpectedly, oseltamivir treatment appeared to have a
positive effect on the proportion of surviving immunocompro-
mised animals and animal body weight loss (Figure 5). Without
oseltamivir treatment, half of the wild type infected group of
animals had succumbed by day 11 and none of the remaining
animals survived the complete 21 day experiment (0/6)
(Figure 5A). However, when oseltamivir therapy was started
24 hours after infection, half of the animals were still alive at day
16 and these remaining animals all survived until day 21 (3/6).
Of the immunocompromised ferrets, which were infected with
the resistant virus (Figure 5B), half of the untreated animals had
died before day 13, but two of the untreated animals and four of
the treated animals survived the complete 21 day experiment.
In addition, oseltamivir treatment appeared to have a
protective effect on body weight loss of the immunocompro-
mised animals (Figure 5C and D). This trend was observed for
both wild type and oseltamivir resistant virus infected groups,
although statistical significant differences was found only for the
wild type infected animals on day 12 when three animals were
still alive (groups 2 versus 3; P= 0.03), and not for the
oseltamivir resistant virus infected animals (groups 5 versus 6;
P= 0.07).
Table 2. Steady-state (day 4) pharmacokinetic parameters for mycophenolic acid, tacrolimus, oseltamivir phosphate and
oseltamivir carboxylate in ferrets (n = 4).
Dose (mg/kg)a Tmax (h) t1/2 (h) Cmax (ng/mL) Ct=12 (ng/mL) AUC0–12 (ng?h/mL)
Immune suppressants
Mycophenolic acid (MPA) 20.0 0.3360.18 0.7360.36 65620 (6103) ,0.1 54620a (6103)b
Tacrolimus 1.0c 0.7960.58 3.6062.29 86630 14614d 4386265
Oseltamivir
Oseltamivir phosphate (OS) 10.0 1.0060.71 3.2260.51 20636579 16617 649161300
Oseltamivir carboxylate (OSC) 4.0060.00 7.9961.17 30526448 8336247 2050164005e
aOral administration twice daily.
bProposed human plasma levels (AUC0–12): 30–60 mg?h/mL [36].
cDose adjusted to 0.5 mg/kg in the infection experiment.
dProposed human whole blood trough levels (Ct= 12): 5–15 ng/mL [37].
ePreviously determined human plasma levels (AUC0–12): 32206982 ng?h/mL (75 mg b.i.d.), 1010062710 ng?h/mL (225 mg b.i.d.) and 1990064840 ng?h/mL (450 mg
b.i.d.) [53].
doi:10.1371/journal.ppat.1003343.t002
Table 1. Immune status and antiviral therapy of 2009 pandemic influenza A virus infected patients hospitalized in our tertiary
hospital between August 2009 and July 2012.
Total hospitalized influenza A virus infected patientsa,b,c n = 189 (%)
Immunocompromised patients 71 (38)
Cause of compromised immune status (n =71)
Cancer chemotherapy 41 (58)
Solid organ transplant recipients 12 (17)
Auto-immune disease 7 (10)
HIV/AIDSd 3 (4)
Othere 8 (11)
Antiviral therapy Immunocompromised All Hospitalized
Any 54 (76) 137 (72)
Oseltamivir monotherapy 44 (62) 117 (62)
Zanamivir monotherapy 1 (1) 1 (,1)
Combination therapy 9 (13) 19 (10)
None 17 (24) 50 (26)
Unknownf None 2 (1)
aInfluenza A virus was detected by an influenza A virus real-time quantitative polymerase-chain-reaction (RT-qPCR) detection assay in respiratory specimens from a total
number of 335 admitted patients between August 2009 and July 2012.
bClinical data were extracted from hospitalized patient records.
cAge (mean= 29.4, median = 22.3, range = 0–81).
dOnly classified as immunocompromised when CD4+ cell count was lower than 350 cells per ml.
eThree patients used high doses of corticosteroids for an endocrine, respiratory or nephrological disease. Three patients had a primary immunodeficiency and 1 patient
had a congenital syndrome. One patient was prematurely born.
fTwo patients had been transferred to another hospital.
doi:10.1371/journal.ppat.1003343.t001
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Discussion
Here we show that prolonged influenza virus shedding and the
emergence of oseltamivir resistance are two phenomena com-
monly observed in immunocompromised patients during antiviral
therapy. As resistance development is low (19 out of 874 (2.2%))
treated influenza virus infected patients [41], the incidence in
immunocompromised patients appears to be considerably higher.
Of all 71 immunocompromised patients infected with an
influenza A virus in our hospital, at least 16 (23%) (11 pH1N1
and 5 H3N2) showed virus persistence for longer than 2 weeks
with 5 of them harbouring oseltamivir resistant virus (5/16)
(31%). Because 52% of the included patients were sent home
before a virus negative follow-up sample had marked the end of
infection, final conclusions on the true incidence of prolonged
virus shedding and development of oseltamivir resistant virus
cannot be made. However, this observation is in line with
previously observed high resistance levels (33%) among paediatric
cancer patients [35], and stresses the importance of a thorough
evaluation of the currently used antiviral therapies in immuno-
compromised patients.
Since for both logistic and ethical reasons randomized studies
are difficult to perform in often critically ill immunocompromised
patients, we showed that prolonged influenza virus replication is
also a common feature in immunocompromised ferrets. We
observed an absence of a rise in body temperature, reduction of
lymphocyte proliferation and follicle formation in ferret lymphoid
tissues, which are also hallmarks in immunocompromised patients
[42] and found a significant reduction of influenza virus specific
antibodies in serum.
In the 2007/2008 H1N1 virus season an H275Y oseltamivir
resistant mutant emerged, which had completely overtaken the
circulating virus population by the end of 2008 [43]. This
introduction of the H275Y mutation disqualified oseltamivir as the
first line antiviral drug. It might happen again with pH1N1 virus if
it would also harbour the H275Y mutation without loss of viral
fitness. Recent reports on clusters of transmitted pH1N1 H275Y
mutant viruses are the first indication that this may not be an
unlikely scenario [44,45]. Early studies on H275Y pH1N1 viral
fitness were performed on viruses isolated shortly after the start of
the 2009 pandemic. These viruses were found to be at least slightly
compromised in their pathogenicity and replication capacity
[46,47,48,49]. We also used an early H275Y virus isolate in our
experiment [38]. If virus replication is not tempered by adequate
immune responses, duration of virus shedding will eventually be
Figure 2. Ferrets on immune suppressive therapy show defective immune function. (a) Schematic of the experimental setup in which 6
groups of ferrets (n = 6) were infected on day 0 with wild type (WT; groups 1–3; green) or oseltamivir resistant (H275Y) mutant virus (groups 4–6;
magenta). Three days before, immune suppressive therapy was started and added to the antibacterial cocktail of groups 2, 3, 5 and 6. Oseltamivir
therapy was added to the drug regime of groups 3 and 6, 24 hours after infection. (b) Reduction of pH1N1 virus specific serum hemagglutination
inhibiting (HI) antibody titers in the remaining (n = 14) immunocompromised ferrets compared to control (n = 12) ferrets. Data are mean 6 s.e.m. The
P value was calculated by Mann-Whitney U test. (c) Body temperature profiles show the absence of body temperature rise during the acute stage of
infection in immunocompromised ferrets. Data are mean6 s.e.m. The P value was calculated by unpaired Student’s t test. (d) Lymphoid tissues show
deficient lymphoid follicle formation in lymph nodes and lymphocyte depletion in the tonsils of immunocompromised ferrets. Representative
photomicrographs of tracheobronchial lymph nodes (original magnification 256) and tonsils (original magnification 506). Tissues were stained with
hematoxylin and eosin (H&E).
doi:10.1371/journal.ppat.1003343.g002
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restricted by an exhaustion of susceptible host target cells. This
then may explain why replication of this apparently less
pathogenic virus lasted longest in our immunocompromised
ferrets (Figure 3D). Priority should now be given to study the
overall fitness of these recent pH1N1 viruses that appear not to be
affected by the H275Y change. The use of our immunocompro-
mised ferrets seems to be a very suitable strategy for this purpose,
because subtle fitness costs may be amplified in these animals [50].
In our study, immunocompromised ferrets were treated with an
oseltamivir dose of 10 mg/kg twice daily. This dose is equivalent
to a much higher human dose than the currently recommended
dose of 75 mg twice daily [51]. We observed that, for animals
infected with either wild type or H275Y mutant virus, high dose
oseltamivir treatment was still beneficial. Currently the World
Health Organisation recommends switching to zanamivir when
dealing with such a resistant virus [52]. However, in the light of
our data, discontinuation of oseltamivir therapy may not always be
the best strategy. An increased oseltamivir dose for the treatment
of immunocompromised patients may be considered as a future
antiviral strategy. However, obviously this will need further clinical
investigation first. Of note, an increased dose of oseltamivir is well
tolerated in humans [53]. We observed lower mortality in the
treated animals infected with H275Y mutant virus without an
observed difference in virus titers in the upper respiratory tract. In
these ferrets, oseltamivir carboxylate plasma levels peaked (Cmax)
from 3052 ng/ml in 4 hours to 833 ng/ml 12 hours after
administration (Table 2 and Figure S1C). These levels were still
about 100 and 30 times higher than the 50% inhibitor
concentration of an H275Y mutant virus, which is roughly
30 ng/ml (,100 nM) [54]. It is therefore plausible that oseltami-
vir therapy reduced H275Y mutant virus titer in the lungs, but not
in the upper respiratory tract. This had been observed before and
could explain the lower mortality rates in the treated animals [55].
It will therefore be of interest to study penetration of oseltamivir
throughout the ferret respiratory tract in more detail, which may
be expected to have a direct impact on the effectiveness of the
presently recommended human dose in immunocompromised
ferrets. In conclusion, both our clinical observations and ferret
experiments show that viral clearance cannot be achieved in the
immunocompromised host solely by the use of currently used
antiviral therapy. Our immunocompromised ferrets may therefore
be an excellent alternative to evaluate and explore novel
therapeutic and immunization strategies for immunocompromised
patients.
Materials and Methods
Patient inclusion criteria and diagnostics
We identified patients hospitalized in the Erasmus Medical
Centre (ErasmusMC), a large (.40,000 admissions in 2011)
tertiary university hospital in the Netherlands, with an influenza A
virus positive respiratory specimen taken between August 2009
Figure 3. Prolonged virus replication in the upper respiratory tract of immunocompromised ferrets. Influenza virus titers were
determined in nose and throat swabs daily taken from immunocompetent (blue lines) and immunocompromised ferrets (red lines). The animals were
infected either with wild type (WT; green; a, b) or mutant virus (H275Y; magenta; c, d). The dotted line in each figure indicates the LLOD. Data are
mean 6 s.e.m. P values were calculated, until day 7, when all animals (n = 6) were still present in each group, by two-tailed Mann-Whitney U test
comparing virus titers between untreated and oseltamivir (OS) treated immunocompromised ferret groups. By day 17, no ferrets were remaining in
group 2.
doi:10.1371/journal.ppat.1003343.g003
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through July 2012. Patients had a prolonged virus infection if the
virus could still be detected after 14 days. Virological data, patient
immune status and administration of antiviral therapy were
obtained by reviewing medical records. Immunosuppression was
defined as any of the following: receipt of treatment for any cancer,
the use of any immunosuppressive medication to prevent
transplant rejection or for management of pulmonary or
autoimmune conditions, premature birth and below gestational
age or a diagnosis of AIDS. Influenza A virus and the H275Y
oseltamivir resistance mutation were detected by reverse tran-
scriptase RT-PCR assays. These assays have been described
previously [40,56]. Informed consent was waived because patient
inclusion was performed retrospectively and data were anony-
mously stored as agreed by the hospital medical ethical board
(MEC-2012-463)
Viruses used in ferret experiment
Two biologically cloned pH1N1 influenza viruses were used in
this study. Both viruses were isolated from an oseltamivir treated
patient during the first wave of the pandemic in October 2009.
Wild type influenza virus A/Netherlands/1715b/2009 (genbank
ID code: CY065810) and H275Y mutant virus were isolated from
the original quasispecies by co-cultivation of a respiratory sample
in a Madin-Darby Canine Kidney (MDCK) cell culture in a single
passage [38]. Biological clones were then obtained by 3 additional
MDCK passages performed under limiting virus concentrations.
As determined by full-genome Sanger sequencing, the mutant
virus contained, additional to mutation H275Y in the neuramin-
idase, an L233M mutation in PB2 and a V541L mutation in HA.
Ferrets
Animal were housed and experiments were conducted in
strict compliance with European guidelines (EU directive on
animal testing 86/609/EEC) and Dutch legislation (Experi-
ments on Animals Act, 1997). The protocol was approved by the
independent animal experimentation ethical review committee
from the Netherlands Vaccine Institute (permit number
200900201). All experiments were performed under animal
bio-safety level 3 conditions. Animal welfare was observed on a
daily basis, and all animal handling was performed under light
anaesthesia using a mixture of ketamine and medetomidine to
minimize animal suffering. After handling atipamezole was
Figure 4. Emergence of oseltamivir resistance mutation H275Y in influenza virus quasispecies from ferrets infected with wild type
virus. Viral RNA was detected using RT-qPCR in nose and throat swabs taken from immunocompetent (group 1; a) or immunocompromised ferrets
(groups 2; b and 3; c). Ferrets in group 3 were treated with oseltamivir (OS). Bar colours indicate the absence (green) or presence (magenta) of the
oseltamivir resistance mutation H275Y as detected by RT-PCR [40]. If both genotypes were detected in a sample, the proportion is stacked.
doi:10.1371/journal.ppat.1003343.g004
Persisting Influenza in Immunocompromised Host
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administered to antagonize the effect of medetomidine. All
ferrets were eleven-month-old purpose-bred males (body
weights between 1562 and 2362 g) and were seronegative for
Aleutian disease virus and circulating influenza virus (sub) types
A/H1N1, A/H3N2 and B virus. The animals were maintained
in standard housing and were transferred to negatively
Figure 5. Increased survival and reduced loss of body weights of immunocompromised ferrets treated with oseltamivir. Kaplan-
Meier survival curves for groups of immunocompetent ferrets (circles), immunocompromised ferrets (triangles) and immunocompromised ferrets
treated with oseltamivir (squares) (a;b). Groups of ferrets were infected with wild type (green;a;c) or oseltamivir resistant (H275Y) mutant virus
(magenta;b;d). Body weights are displayed from day 0 to day 21, with a two or three days interval (c;d). Data points represent mean 6 s.e.m. of
percentage body weight loss. Body weights at day 0 were set at 100%. The arrow indicates data point of only a single animal. The asterisk indicates
significant difference between untreated and oseltamivir treated immunocompromised animals (P= 0.03). The P value was calculated by a two-tailed
Mann-Whitney U test, when at least 3 animals were present in each group.
doi:10.1371/journal.ppat.1003343.g005
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pressured glove boxed on the day immunosuppressive therapy
was started. They were provided food ad libidum with commer-
cial food pellets and water. Approximately three to four weeks
prior to the experiment a temperature logger (DST micro-T
ultra small temperature logger; Star-Oddi, Reykjavik, Iceland)
was placed in the peritoneal cavity of the animals. This device
recorded the body temperature of the animals every 10 minutes.
From day 28 to day 24, an average baseline temperature was
recorded for each group of 6 animals.
Immunosuppressive, antibiotic and antiviral drugs
The following immunosuppressive drugs were used to suppress
the immune system of ferrets: Mycophenolate mofetil (MMF)
(CellCept, Roche, The Netherlands) powder for infusion,
tacrolimus concentrate (5 mg/ml) for infusion (Prograft, Astellas
Pharma BV, Leiderdorp, The Netherlands) and prednisolone
sodium phosphate (5 mg/ml) oral solution (Hospital Pharmacy,
UMCN St Radboud, Nijmegen, The Netherlands). All ferrets
received an antibiotic prophylaxis of amoxicillin supplemented
with 62.5 mg clavulanic acid (250/62.5 mg per 5 ml) oral
suspension (Pharmachemie BV, Haarlem, The Netherlands).
Prodrug oseltamivir phosphate, used in the ferret experiments,
was kindly provided by Hoffman-La Roche LtD. (Tamiflu, Basel,
Switzerland).
Other chemicals and reagents
Oseltamivir standards for mass spectrometry, oseltamivir
phosphate (OS), oseltamivir-d3 (OS-d3), oseltamivir carboxylate
(OSC) and oseltamivir carboxylate-d3 (OSC-d3) were purchased
from Toronto Research Chemicals (Toronto, Canada). Mycophe-
nolic acid (MPA) standard and internal standards (MPAC) were
purchased from Sigma Aldrich (Zwijndrecht, the Netherlands) and
from Hoffman-La Roche LtD. respectively. The tacrolimus
standards and internal standards (Ascomycin) were purchased
from, respectively, Chromsystems and Sigma Aldrich. ULC/MS
grade methanol and water containing 0.1% formic acid were
obtained from Biosolve (Valkenswaard, the Netherlands). Tri-
chloro acetic acid (TCA) and formic acid (.96%, HCOOH) were
obtained from Sigma Aldrich and both were from ACS reagent
quality.
Administration of the drugs
A schematic of the ferret experiment is presented in Figure 2A.
Shortly before gavage, drugs were prepared as follows: MMF was
dissolved in a 5% glucose solution (Baxter, Unterschleisheim,
Germany) to 33 mg/ml. Amoxicillin/clavulanic acid was diluted 5
times in water to obtain a suspension containing 50/12.5 mg/ml
amoxicillin/clavulanic acid. Oseltamivir phosphate was dissolved
in 5% glucose to 20 mg/ml. These intermediate preparations and
the ready-to-use tacrolimus and prednisolone solutions were then
used to dose the animals orally and twice daily, as follows: four
days before infection, all 6 groups received 10/2.5 mg/kg
amoxicillin/clavulanic acid diluted in 5% glucose to a final
administration volume of 4 ml/kg. One day later, antibiotic
prophylaxis was supplemented to the regimes of groups 2, 3, 5 and
6 with 20 mg/kg MMF, 0.5 mg/kg tacrolimus and 8 mg/kg
prednisolone retaining the administration volume of 4 ml/kg. On
day 1, 24 hours after infection, therapy of group 3 and 6 was
further supplemented with 10 mg/kg oseltamivir phosphate for
the remaining 20 days of the experiment. The dose of
prednisolone was halved every 7 days from 8 mg/kg in the first
to 1 mg/kg in the last week.
Virology and serology
On day 0, three days after start of immunosuppressive therapy,
ferrets were intratracheally infected with 16104 TCID50 of wild
type (groups 1, 2 and 3) or mutant virus (groups 4, 5 and 6). Each
day, pharyngeal and nasal swabs were collected just before
administration of the drugs. Swabs were resuspended in 3 ml virus
transport medium [57], and aliquots were made and used either
directly for online detection of viral RNA by RT-PCR or stored at
280uC for retrospective virus titration. An electron microscopy
counted influenza A virus stock was run in parallel to convert RT-
PCR cycle threshold (CT) values into a viral particle count. Blood
samples for serum and plasma were collected on day 13 after
infection. Influenza antibody titers were determined as described
previously [58].
Oseltamivir blood plasma levels
Oseltamivir and MMF plasma levels and whole blood
tacrolimus levels were determined in a pharmacokinetic pilot
study. For 4 days, four groups of ferrets (n = 4) received MMF,
tacrolimus, or oseltamivir in combination with amoxicillin/
clavulanic acid and prednisolone or as the complete cocktail. On
day 4, blood was collected from these animals after 0, 10, 20,
30 minutes and 1, 2, 4, 5, 8 and 12 hours after administration of
the drugs in order to determine MMF and tacrolimus levels, as
described previously [59, unpublished data]. Ferret oseltamivir
plasma levels were determined as described previously with some
modifications [60]. Calibrators used for the determination of the
calibration curve of OS and OSC were prepared from one single
stock solution in plasma each containing 50 mg/ml. Calibrators
were then prepared by serial dilutions using drug-free plasma.
Calibrators for OS and OSC yielded following concentrations:
5000, 1500, 750, 500, 250, 150, 50, 12.5, 2.5 and 0 ng/ml (blank).
Aliquots of 50 ml were spiked with 5 ml internal standard solution
containing 50 mg/ml OS-d3 and OSC-d3. To calibrators and
ferret plasma (K2EDTA) samples, 5 ml of a 50% TCA solution (w/
v) was added for plasma protein precipitation. Precipitated plasma
proteins were removed by centrifugation for 10 minutes at
20006g at ambient temperature. De-proteinized plasma samples
(20 ml) were 2.5 times diluted with ultrapure water and 40 ml of the
diluted samples were injected by an auto-sampler (kept at 4uC)
into the liquid chromatography mass spectrometry (LC-MS)
system. The calibration curves for OS and OSC showed a linear
relationship between the SRM peak area of ratios between OS/
OS-d3 and OSC/OSC-d3, respectively (OS; r2 = 0.9966 and
OSC; r2 = 0.9970). The LLOQ and LOD were determined
according to FDA guidelines and were, respectively, 2.5 and
1.0 ng/ml for both OS and OSC. The LC-MS system used was an
4000 API triple quadruple mass spectrometer containing a Turbo
V electron spray ion source (ESI) (AB Sciex, Concord, Canada)
operating in the positive ionization mode using selected reaction
monitoring (SRM) in combination with a Dionex Ultimate 3000
UHPLC system (Amsterdam, the Netherlands) using an Ascentis
Express RP-C18 column (10062.1, 2.7 mm, Supelco, Munich)
applying a gradient separation at 30uC.
Pathology
Samples for histological examination of the tonsils and
tracheobronchial lymph nodes were taken to evaluate the immune
status and were stored in 10% neutral-buffered formalin.
Subsequently, these were routinely processed and embedded in
paraffin wax, sectioned at 4 mm and stained with haematoxylin
and eosin (HE) for examination by light microscopy.
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Statistical analysis
Data are reported as mean 6 standard error of the mean
(s.e.m). The P values for comparison of influenza HI antibody
titers in figure 2B, virus titers in figure 3 and body weight loss in
figure 5C were calculated using Mann-Whitney U test only if at
least three animals were remaining in each experimental group.
P#0.05 was considered significant.
Supporting Information
Figure S1 Mean steady state (day 4) pharmacokinetics of MMF,
tacrolimus and oseltamivir in ferrets. Twice daily, four ferrets were
given a cocktail of antibacterial prophylaxis, immune suppressive
therapy (a; b) and oseltamivir phosphate (c) for 4 days. On day 4,
blood was collected after 0, 10, and 30 minutes and 1, 2, 4, 5, 8
and 12 hours after the final cocktail was administered. Plasma
levels of the active form of mycophenolate mofetil (MMF), the
metabolite mycophenolic acid (MPA) (a), whole blood tacrolimus
levels (b), oseltamivir phosphate (black squares; c) and its
metabolite oseltamivir carboxylate (grey squares; c) plasma levels
were determined by mass spectrometry. Area under the curve
(AUC0–12), peak (Cmax) and trough (C12) levels and half-life (t1/2)
values are presented in table 2. Data are mean 6 s.e.m..
(TIF)
Figure S2 Ferrets on immune-suppressive therapy show reduced
antibody titers. Reduction of serum hemagglutination inhibiting
(HI) antibody titers against pH1N1 A/NL/602/2009 virus (a) and
more distant viruses A/sw/NL/25/80 (b), A/IT/1443/76 (c), and
A/New Jersey/08/76 (d). Individual data points represent antibody
titers for each animal and horizontal bars represent the mean titer
per group. Body temperature profiles show the absence of fever
during the acute stage of infection in ferrets infected with wild type
(e) or mutant (f) virus. Animals in this experiment were either
immunocompetent (circles), immunocompromised (triangles) or
immunocompromised and oseltamivir treated (squares). Data are
mean6 s.e.m. Data used for Figure 2B are marked with an asterisk.
(TIF)
Figure S3 Total number of animals positive for replication
competent influenza virus in the upper respiratory tract. Influenza
virus titers (TCID50/ml) were determined in nose and throat
swabs daily taken from immunocompetent (blue bars; group 1 and
4) and immunocompromised ferrets (red bars; group 2, 3, 5 and 6).
The animals were infected either with wild type (WT; a, b) or
mutant virus (H275Y; c, d). Ferrets in groups 3 and 6 were treated
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